OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 yearsWilliam J. Sandborn, Brian G. Feagan, P. Rutgeerts et al.|Journal of Crohn s and Colitis|2017Cited by 13
OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITIWJ Sandborn, C Gasink, L-L Gao et al.|Unknown|2016Cited by 11
LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARSWilliam J. Sandborn, Bruno Silva, P. Rutgeerts et al.|Arquivos Brasileiros de Cirurgia Digestiva Express|2017Cited by 6
OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2B. Feagan, WJ Sandborn, Christopher Gasink et al.|Unknown|2016Cited by 6
Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs diseaseBE Sands, B. Feagan, Christopher Gasink et al.|Inflammatory Bowel Diseases|2011Cited by 5